The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

Study Overview
=================
Brief Summary
-----------------
Neurocognitive disorders and hypertension occur commonly with aging. While, by definition, older adults are at high cardiovascular risk, there is no guideline exist currently on blood pressure management of elderly hypertension. However, studies have shown that in aging adults, high blood pressure helps prevent against cognitive decline, and low blood pressure on antihypertensive drugs could accelerate it. This study aims at investigating if pharmacological treatment of hypertension in the very elderly is influenced by presence and severity of neurocognitive disorders. Our research hypothesis is that the drug management of hypertension in patients 80 years of age or older more is all the less aggressive as the neurocognitive disorders are advanced.

Official Title
-----------------
The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Very Elderly: the TAHOC Study

Conditions
-----------------
Neurocognitive Disorders, Dementia, Hypertension, Aged, 80 and Over

Intervention / Treatment
-----------------
* Drug: Antihypertensive Agents


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: to be 80 years of age with history of hypertension and/or on hypertensive drug(s) Exclusion Criteria: legal protection measure.

Ages Eligible for Study
-----------------
Minimum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control group<br>absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive | Drug: Antihypertensive Agents<br>* number of hypertensive drugs<br>|
| mild neurocognitive disorder<br>MMSE from 21 to 26 inclusive | Drug: Antihypertensive Agents<br>* number of hypertensive drugs<br>|
| moderate neurocognitive disorder<br>MMSE from 11 to 20 inclusive | Drug: Antihypertensive Agents<br>* number of hypertensive drugs<br>|
| severe neurocognitive disorder<br>MMSE less than or equal to 10 | Drug: Antihypertensive Agents<br>* number of hypertensive drugs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of antihypertensive agents | among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker | during inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| class of antihypertensive medications | among ACEI/ARB2, calcium channel blocker, thiazides and related, central antihypertensive beta blocker | during inclusion | 
| systolic and diastolic blood pressure | blood pressure measured with upper arm cuffs | during inclusion | 
| orthostatic hypotension | a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing | during inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neurocognitive Disorders, Dementia, Hypertension, Aged, 80 and over